Roche fails to balance declining Tamiflu sales
This article was originally published in Scrip
Executive Summary
Declining sales of Tamiflu coupled with the strong Swiss franc have continued to hurt Roche, which posted a decline of 2% in group sales to CHF33.31 billion ($29.23 billion) in the first nine months of 2008.